Abstract P368: Effects of Empagliflozin on Day-to-day Variability of Home Blood Pressure and Heart Rate in Patients with Type 2 Diabetes

Abstract

Background: The effects of empagliflozin in addition to standard care, on day-to-day variability of self-measured home blood pressure (BP) and heart rate (HR) at home in patients with type 2 diabetes (T2DM) at high cardiovascular risk are not known. Method: We followed twenty-three consecutive T2DM patients (mean age: 69 years old, 12 men) to add 10 mg of empagliflozin once daily for three months. Home BP and HR were measured once every morning at home, using an oscillometric device. The variability of BP and HR were defined as the standard deviations (SD) of measurements which were performed on seven consecutive days. Results: For home blood pressure, empagliflozin significantly reduced systolic blood pressure (SBP) from 130±11 mmHg at baseline to 126±11 mmHg at the first week(1W) of the administration (P<0.05). SBP achieved the target home BP goal (125±11 mmHg) at the second week(2W) and was maintained during the study (P<0.01). As regards day-to-day variability of SBP, SD decreased from 7.3±3.5 mmHg at baseline to 6.7±2.5 mmHg at 1W (4W: 6.4±2.8 mmHg, 8W: 5.2±2.3 mmHg, P<0.05). In diastolic blood pressure (DBP), there was a significant reduction of SD compared with that at baseline (4.9±1.6 mmHg at baseline, 4W: 4.3±1.6 mmHg, 8W: 3.9±1.8 mmHg, 12W: 4.4±1.6 mmHg, P<0.05); however, there was no change of DPB (71±10 mmHg at baseline, 12W: 71±8 mmHg). Similarly, there was a decreasing trend in SD of HR (3.9±1.0 beats per minute (bpm) at baseline, 4W: 3.3±1.3 bpm, 12W: 3.1±1.3 bpm, P<0.1), although there was no significant change in HR (62±13 bpm at baseline, 12W: 61 ± 12 bpm). Conclusion: Empagliflozin tended to reduce the day-to-day variability of self-measured morning home BP and HR.